MSD-话题@MedSci - 梅斯（MedSci）

#MSD#

14篇内容 | 1219人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=MSD与Promega合作开发Keytruda伴侣诊断，以判断哪些患者会受益于PD-1抑制剂的治疗, objectType=article, longId=182746, objectId=ca52182e4662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca52182e4662, replyNumber=0, likeNumber=67, createdTime=2019-11-11, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca52182e4662, moduleTitle=MSD与Promega合作开发Keytruda伴侣诊断，以判断哪些患者会受益于PD-1抑制剂的治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ca52182e4662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527017, encodeId=fbba152e0170b, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=75, createdTime=2019-08-17, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527016, encodeId=1663152e0161f, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, objectType=article, longId=177339, objectId=a5a91e73396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5a91e73396a, replyNumber=0, likeNumber=90, createdTime=2019-08-11, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5a91e73396a, moduleTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a5a91e73396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527015, encodeId=5b96152e01509, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着, objectType=article, longId=167750, objectId=63b216e750f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63b216e750f8, replyNumber=0, likeNumber=90, createdTime=2019-06-07, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63b216e750f8, moduleTitle=2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=63b216e750f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527014, encodeId=291a152e01445, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制, objectType=article, longId=167613, objectId=b87a16e61344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b87a16e61344, replyNumber=0, likeNumber=87, createdTime=2019-06-05, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b87a16e61344, moduleTitle=英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b87a16e61344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527013, encodeId=c55b152e0130d, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功, objectType=article, longId=161224, objectId=fd561612244e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd561612244e, replyNumber=0, likeNumber=72, createdTime=2019-02-28, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd561612244e, moduleTitle=AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fd561612244e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527012, encodeId=94e8152e01249, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=Eisai/MSD的Lenvima在欧洲被批准用于肝癌的治疗, objectType=article, longId=147384, objectId=744714e38490, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=744714e38490, replyNumber=0, likeNumber=77, createdTime=2018-08-27, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=744714e38490, moduleTitle=Eisai/MSD的Lenvima在欧洲被批准用于肝癌的治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=744714e38490)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527011, encodeId=acc2152e011dd, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤, objectType=article, longId=145835, objectId=24c4145835bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24c4145835bc, replyNumber=0, likeNumber=72, createdTime=2018-08-05, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24c4145835bc, moduleTitle=EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=24c4145835bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527010, encodeId=9094152e01021, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=NICE认为MSD的Keytruda作为一线肺癌治疗具有成本效益, objectType=article, longId=140288, objectId=4554140288e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4554140288e6, replyNumber=0, likeNumber=86, createdTime=2018-06-09, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4554140288e6, moduleTitle=NICE认为MSD的Keytruda作为一线肺癌治疗具有成本效益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4554140288e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527009, encodeId=7943152e009c6, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=欧盟审查MSD的Keytruda / chemo组合, objectType=article, longId=136382, objectId=68d113638240, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68d113638240, replyNumber=0, likeNumber=65, createdTime=2018-04-26, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68d113638240, moduleTitle=欧盟审查MSD的Keytruda / chemo组合, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=68d113638240)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527008, encodeId=df0c152e0084c, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=MSD的keytruda在非小细胞肺癌的另一项临床试验中大获成功, objectType=article, longId=134813, objectId=9aa4134813ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aa4134813ac, replyNumber=0, likeNumber=78, createdTime=2018-04-12, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aa4134813ac, moduleTitle=MSD的keytruda在非小细胞肺癌的另一项临床试验中大获成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9aa4134813ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527007, encodeId=5dca152e0076c, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=MSD/Eisai癌症组合获美国突破性疗法认定, objectType=article, longId=126183, objectId=a02312618301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a02312618301, replyNumber=0, likeNumber=65, createdTime=2018-01-12, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a02312618301, moduleTitle=MSD/Eisai癌症组合获美国突破性疗法认定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a02312618301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527006, encodeId=5d9a152e006a6, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=MSD骨质疏松症药物Odanacatib达3期试验主要终点, objectType=article, longId=40667, objectId=895d4066e16, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=895d4066e16, replyNumber=0, likeNumber=69, createdTime=2014-09-27, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=895d4066e16, moduleTitle=MSD骨质疏松症药物Odanacatib达3期试验主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=895d4066e16)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1527005, encodeId=98f1152e005b7, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, objectTitle=MSD失眠症药物Suvorexant获FDA批准希望大增, objectType=article, longId=19376, objectId=329e193e644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=329e193e644, replyNumber=0, likeNumber=71, createdTime=2013-05-30, rootId=0, userName=zhangj7112, userId=b75211789652, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=329e193e644, moduleTitle=MSD失眠症药物Suvorexant获FDA批准希望大增, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=329e193e644)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MSD

2020-05-29

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

MSD与Promega合作开发Keytruda伴侣诊断，以判断哪些患者会受益于PD-1抑制剂的治疗

2019-11-11

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2019-08-17

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

2019-08-11

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着

2019-06-07

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制

2019-06-05

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功

2019-02-28

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

Eisai/MSD的Lenvima在欧洲被批准用于肝癌的治疗

2018-08-27

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

EMA授予AZ和MSD公司MEK抑制剂孤儿药资格用于治疗1型神经纤维瘤

2018-08-05

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

NICE认为MSD的Keytruda作为一线肺癌治疗具有成本效益

2018-06-09

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

欧盟审查MSD的Keytruda / chemo组合

2018-04-26

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

MSD的keytruda在非小细胞肺癌的另一项临床试验中大获成功

2018-04-12

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

MSD/Eisai癌症组合获美国突破性疗法认定

2018-01-12

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

MSD骨质疏松症药物Odanacatib达3期试验主要终点

2014-09-27

zhangj7112 (审核中...)

前往app查看评论内容

#MSD#

MSD失眠症药物Suvorexant获FDA批准希望大增

2013-05-30

科室
- - 订阅+
  - 更多科室
工具
服务